- Home
- People Index
- Marita Ziepert
Health Atlas ID: 7W2GJTH8AW-5
Location:
Germany
Expertise: Not specified
Tools: Not specified
ORCID: Not specified
Related items
- Projects (1)
- Institutions (1)
- Investigations (17)
- Studies (15)
- Resources (18)
- Publications (40)
- Data files (50)
- Models (1)
B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study
...
Programme: NHL
Public web page: https://www.dshnhl.org
Organisms: Homo sapiens
Human Diseases: non-Hodgkin lymphoma, B-cell lymphoma
Snapshots: No snapshots
Studies: MAXSEP
Resources: MAXSEP Trial Data, MAXSEP Trial Metadata
Mega-CHOEP phase III is a randomised study comparing conventional chemoimmunotherapy with R-CHOEP-14 with high-dose chemotherapy plus Rituximab with autologous stem cell transplantation in high-risk patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
Snapshots: No snapshots
Studies: MegaCHOEP Phase III
Resources: No Resources
RICOVER-60 is a randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
Snapshots: No snapshots
Studies: RICOVER-60
Resources: RICOVER-60 trial data, RICOVER-60 trial metadata
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Snapshots: No snapshots
Studies: SEXIE-R-CHOP-14
Resources: SEXIE-R-CHOP-14 metadata, SEXIE-R-CHOP-14 trial data
Snapshots: No snapshots
Studies: SMARTE-R-CHOP-14
Resources: SMARTE-R-CHOP-14 metadata, SMARTE-R-CHOP-14 trial data
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Investigation: SEXIE-R-CHOP-14
Resources: SEXIE-R-CHOP-14 metadata, SEXIE-R-CHOP-14 trial data
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Sample Size: 189
Submitter: René Hänsel
Resource type: Experimental Assay Type
Technology type: Technology Type
Snapshots: No snapshots
Investigation: SMARTE-R-CHOP-14
Study: SMARTE-R-CHOP-14
Organisms: No organisms
Human Diseases: B-cell lymphoma
SOPs: No SOPs
Data files: SMARTE-R-CHOP-14 trial data-CSV, SMARTE-R-CHOP-14 trial data-ODM, SMARTE-R-CHOP-14 trial data-SPSS
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Sample Size: 189
Submitter: René Hänsel
Resource type: Experimental Assay Type
Technology type: Technology Type
Snapshots: No snapshots
Investigation: SMARTE-R-CHOP-14
Study: SMARTE-R-CHOP-14
Organisms: No organisms
Human Diseases: B-cell lymphoma
SOPs: No SOPs
Data files: SMARTE-R-CHOP-14 metadata-ODM, SMARTE-R-CHOP-14 metadata-XLSX
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Sample Size: 268
Submitter: René Hänsel
Resource type: Experimental Assay Type
Technology type: Technology Type
Snapshots: No snapshots
Investigation: SEXIE-R-CHOP-14
Study: SEXIE-R-CHOP-14
Organisms: No organisms
Human Diseases: diffuse large B-cell lymphoma
SOPs: No SOPs
Data files: SEXIE-R-CHOP-14 trial data-CSV, SEXIE-R-CHOP-14 trial data-ODM, SEXIE-R-CHOP-14 trial data-SPSS
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Sample Size: 268
Submitter: René Hänsel
Resource type: Experimental Assay Type
Technology type: Technology Type
Snapshots: No snapshots
Investigation: SEXIE-R-CHOP-14
Study: SEXIE-R-CHOP-14
Organisms: No organisms
Human Diseases: diffuse large B-cell lymphoma
SOPs: No SOPs
Data files: SEXIE-R-CHOP-14 metadata-ODM, SEXIE-R-CHOP-14 metadata-XLSX
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Submitter: René Hänsel
Resource type: Experimental Assay Type
Technology type: Technology Type
Snapshots: No snapshots
Investigation: RICOVER-noRTh
Study: RICOVER-noRTh
Organisms: No organisms
Human Diseases: B-cell lymphoma
SOPs: No SOPs
Data files: RICOVER-noRTh trial data-CSV, RICOVER-noRTh trial data-ODM, RICOVER-noRTh trial data-SPSS
Abstract (Expand)
Authors: Q. Shi, N. Schmitz, F. S. Ou, J. G. Dixon, D. Cunningham, M. Pfreundschuh, J. F. Seymour, U. Jaeger, T. M. Habermann, C. Haioun, H. Tilly, H. Ghesquieres, F. Merli, M. Ziepert, R. Herbrecht, J. Flament, T. Fu, B. Coiffier, C. R. Flowers
Date Published: 1st Sep 2018
Publication Type: Not specified
Human Diseases: diffuse large B-cell lymphoma
PubMed ID: 29975624
Citation: J Clin Oncol. 2018 Sep 1;36(25):2593-2602. doi: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.
Abstract (Expand)
Authors: M. J. Maurer, T. M. Habermann, Q. Shi, N. Schmitz, D. Cunningham, M. Pfreundschuh, J. F. Seymour, U. Jaeger, C. Haioun, H. Tilly, H. Ghesquieres, F. Merli, M. Ziepert, R. Herbrecht, J. Flament, T. Fu, C. R. Flowers, B. Coiffier
Date Published: 1st Aug 2018
Publication Type: Not specified
Human Diseases: diffuse large B-cell lymphoma
PubMed ID: 29897404
Citation: Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.
Abstract (Expand)
Authors: B. Chapuy, C. Stewart, A. J. Dunford, J. Kim, A. Kamburov, R. A. Redd, M. S. Lawrence, M. G. M. Roemer, A. J. Li, M. Ziepert, A. M. Staiger, J. A. Wala, M. D. Ducar, I. Leshchiner, E. Rheinbay, A. Taylor-Weiner, C. A. Coughlin, J. M. Hess, C. S. Pedamallu, D. Livitz, D. Rosebrock, M. Rosenberg, A. A. Tracy, H. Horn, P. van Hummelen, A. L. Feldman, B. K. Link, A. J. Novak, J. R. Cerhan, T. M. Habermann, R. Siebert, A. Rosenwald, A. R. Thorner, M. L. Meyerson, T. R. Golub, R. Beroukhim, G. G. Wulf, G. Ott, S. J. Rodig, S. Monti, D. S. Neuberg, M. Loeffler, M. Pfreundschuh, L. Trumper, G. Getz, M. A. Shipp
Date Published: 2nd May 2018
Publication Type: Not specified
Human Diseases: diffuse large B-cell lymphoma
PubMed ID: 29713087
Citation: Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30.
Abstract (Expand)
Authors: K. Hohloch, B. Altmann, M. Pfreundschuh, M. Loeffler, N. Schmitz, F. Zettl, M. Ziepert, L. Trumper
Date Published: 2nd Dec 2017
Publication Type: Not specified
Human Diseases: obesity, B-cell lymphoma
PubMed ID: 29193018
Citation: Br J Haematol. 2018 Jan;180(2):236-245. doi: 10.1111/bjh.15029. Epub 2017 Nov 28.
Abstract (Expand)
Authors: B. Glass, A. J. Dohm, L. H. Truemper, M. Pfreundschuh, A. Bleckmann, G. G. Wulf, A. Rosenwald, M. Ziepert, N. Schmitz
PubMed ID: 29232438
Citation: Ann Oncol. 2017 Dec 1;28(12):3058-3064. doi: 10.1093/annonc/mdx556.
Introduction
On this homepage we provide a web-based tool to calculate prognostic scores on haematopoietic toxicity for 6 cycles CHOP-like regimen in patients with aggressive NHL. As we used for this analysis the data collected within the NHL-B1 and NHL-B2 trials of the DSHNHL as described in detail in Pfreundschuh et al. the predictions are valid for similar patient populations.
Description
We offer two types of models. Pre-treatment models include beside the therapy regimen only prognostic
...
Creator: Marita Ziepert
Submitter: René Hänsel
Model type: Not specified
Model format: Not specified
Environment: Not specified
Organism: Not specified
Human Disease: non-Hodgkin lymphoma
Investigations: No Investigations
Studies: No Studies
Resources: No Resources